Remedy’s $18 million round takes total funding to $55 million

Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round.

The round includes participation from Schooner Capital and Alexandria Venture Investments and brings the company’s total funding to date to $55 million.

Funds raised will accelerate the advancement of the company’s first-in-class NAMPT inhibitor, RPT1G, into a Phase I/II study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).